PT3773715T - Miricizumab no tratamento da colite ulcerosa - Google Patents

Miricizumab no tratamento da colite ulcerosa

Info

Publication number
PT3773715T
PT3773715T PT197222565T PT19722256T PT3773715T PT 3773715 T PT3773715 T PT 3773715T PT 197222565 T PT197222565 T PT 197222565T PT 19722256 T PT19722256 T PT 19722256T PT 3773715 T PT3773715 T PT 3773715T
Authority
PT
Portugal
Prior art keywords
methods
ulcerative colitis
treating ulcerative
treating
colitis
Prior art date
Application number
PT197222565T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT3773715T publication Critical patent/PT3773715T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT197222565T 2018-03-30 2019-03-28 Miricizumab no tratamento da colite ulcerosa PT3773715T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30

Publications (1)

Publication Number Publication Date
PT3773715T true PT3773715T (pt) 2024-05-27

Family

ID=66429483

Family Applications (2)

Application Number Title Priority Date Filing Date
PT197222565T PT3773715T (pt) 2018-03-30 2019-03-28 Miricizumab no tratamento da colite ulcerosa
PT232156265T PT4327866T (pt) 2018-03-30 2019-03-28 Mirikizumab no tratamento da colite ulcerosa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT232156265T PT4327866T (pt) 2018-03-30 2019-03-28 Mirikizumab no tratamento da colite ulcerosa

Country Status (29)

Country Link
US (2) US12152072B2 (https=)
EP (2) EP4327866B1 (https=)
JP (4) JP7119114B2 (https=)
KR (1) KR102552693B1 (https=)
CN (1) CN111936165A (https=)
AU (2) AU2019243283C1 (https=)
BR (1) BR112020018099A2 (https=)
CA (1) CA3095297A1 (https=)
DK (2) DK3773715T3 (https=)
EA (1) EA202091989A1 (https=)
ES (2) ES3063700T3 (https=)
FI (2) FI3773715T3 (https=)
HR (2) HRP20240904T1 (https=)
HU (1) HUE067445T2 (https=)
IL (2) IL277514B2 (https=)
LT (2) LT4327866T (https=)
MA (2) MA67901B1 (https=)
MD (1) MD3773715T2 (https=)
MX (1) MX2020010269A (https=)
MY (1) MY202368A (https=)
PL (2) PL3773715T3 (https=)
PT (2) PT3773715T (https=)
RS (2) RS67806B1 (https=)
SG (1) SG11202009526RA (https=)
SI (1) SI3773715T1 (https=)
TW (2) TWI837532B (https=)
UA (1) UA128578C2 (https=)
WO (1) WO2019191464A1 (https=)
ZA (1) ZA202005388B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CA3170677A1 (en) * 2020-02-14 2021-08-19 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
JP2024501900A (ja) * 2021-01-06 2024-01-16 アッヴィ・インコーポレイテッド クローン病及び潰瘍性大腸炎を処置する方法
EP4340875A1 (en) * 2021-05-20 2024-03-27 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP2024521748A (ja) * 2021-05-28 2024-06-04 イーライ リリー アンド カンパニー 潰瘍性大腸炎に関与する遺伝子の抗il-23p19抗体調節
WO2023095000A1 (en) * 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
US20240199734A1 (en) * 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
KR20250156783A (ko) 2023-03-10 2025-11-03 일라이 릴리 앤드 캄파니 궤양성 결장염을 치료하는 방법
CN121443635A (zh) * 2023-06-16 2026-01-30 信达生物医药科技(杭州)有限公司 重组抗白介素23p19亚基抗体在治疗炎症性肠病中的用途
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2026060205A1 (en) 2024-09-13 2026-03-19 Eli Lilly And Company PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006265002B2 (en) * 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
US20110212104A1 (en) * 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PE20141162A1 (es) * 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
CA3092551A1 (en) * 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody

Also Published As

Publication number Publication date
EP4327866A2 (en) 2024-02-28
JP7331219B2 (ja) 2023-08-22
AU2019243283B2 (en) 2023-07-27
JP2025020134A (ja) 2025-02-12
HUE067445T2 (hu) 2024-10-28
AU2023248103B2 (en) 2026-02-05
IL277514B2 (en) 2024-11-01
JP7119114B2 (ja) 2022-08-16
HRP20260275T1 (hr) 2026-04-10
TWI744617B (zh) 2021-11-01
IL312807B1 (en) 2025-02-01
PT4327866T (pt) 2026-02-17
ES3063700T3 (en) 2026-04-20
TW202206104A (zh) 2022-02-16
SI3773715T1 (sl) 2024-06-28
BR112020018099A2 (pt) 2020-12-22
IL312807B2 (en) 2025-06-01
TW201946657A (zh) 2019-12-16
US20210032325A1 (en) 2021-02-04
IL312807A (en) 2024-07-01
EP4327866A3 (en) 2024-03-20
ES2983809T3 (es) 2024-10-24
CA3095297A1 (en) 2019-10-03
IL277514B1 (en) 2024-07-01
RS67806B1 (sr) 2026-03-31
ZA202005388B (en) 2025-05-28
DK3773715T3 (da) 2024-05-27
PL3773715T3 (pl) 2024-08-19
DK4327866T3 (da) 2026-02-23
HRP20240904T1 (hr) 2024-10-11
KR20200128101A (ko) 2020-11-11
US12152072B2 (en) 2024-11-26
EP4327866B1 (en) 2025-12-10
JP7571225B2 (ja) 2024-10-22
FI3773715T3 (fi) 2024-05-30
JP2023166388A (ja) 2023-11-21
LT3773715T (lt) 2024-06-25
RS65661B1 (sr) 2024-07-31
US20250034243A1 (en) 2025-01-30
MY202368A (en) 2024-04-24
EP3773715B1 (en) 2024-05-08
MA52216A (fr) 2021-02-17
CN111936165A (zh) 2020-11-13
AU2019243283A1 (en) 2020-09-24
UA128578C2 (uk) 2024-08-21
AU2019243283C1 (en) 2024-05-02
AU2023248103A1 (en) 2023-11-09
TWI837532B (zh) 2024-04-01
MA67901B1 (fr) 2026-02-27
WO2019191464A1 (en) 2019-10-03
JP2021517156A (ja) 2021-07-15
SG11202009526RA (en) 2020-10-29
MX2020010269A (es) 2020-11-06
KR102552693B1 (ko) 2023-07-07
LT4327866T (lt) 2026-03-10
FI4327866T3 (fi) 2026-02-18
MD3773715T2 (ro) 2024-10-31
IL277514A (en) 2020-11-30
EA202091989A1 (ru) 2021-01-13
JP2022169562A (ja) 2022-11-09
EP3773715A1 (en) 2021-02-17
PL4327866T3 (pl) 2026-04-20
MA52216B1 (fr) 2024-07-31
NZ767902A (en) 2024-05-31

Similar Documents

Publication Publication Date Title
IL277514A (en) Methods for treating ulcerative colitis
ZA202006746B (en) Methods of treatment
ZA201903873B (en) Methods of treating cochlear synaptopathy
EP3319619A4 (en) Methods of treating colitis
IL290069A (en) Methods for treating eye conditions
IL267199A (en) A method for treating epilepsy
GB201706406D0 (en) Method of treatment
EP3684342C0 (en) TREATMENT PROCEDURES
IL256109A (en) Methods for the treatment or prevention of protopathy
LT3661510T (lt) Elgesio pakitimų gydymo būdai
GB201815588D0 (en) Method of treatment
IL279917A (en) Treating ulcerative colitis with brazikumab
PL3356577T3 (pl) Obróbka w kąpieli wytrawiającej
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201602802D0 (en) Method of treatment
SG11202000839TA (en) Methods of treating cancer by inhibiting setd2
ZA201903931B (en) Method of treating meat
SG11201710199PA (en) Methods of treating multiple sclerosis
PT3661510T (pt) Métodos de tratamento de alterações do comportamento
GB201820157D0 (en) Method of treatment
GB201720439D0 (en) Method of treatment
GB201718589D0 (en) Method of treatment
ZA201805402B (en) Treatment of contaminated water
GB201801249D0 (en) Methods of treatment
GB201709554D0 (en) Method of treatment